CYPH

Leap Therapeutics, Inc. (LPTX) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2024. Leap Therapeutics, Inc. is a biopharmaceutical company developing biomarker-targeted antibody therapies for cancer. The company has no approved products and generates no product revenue. Its primary focus is the clinical development of DKN-01 (targeting DKK1) and FL-301 (targeting Claudin18.2), alongside preclinical programs FL-302 and FL-501.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company recorded $0.3 million in Australian R&D incentive income for Q2 2024.

Material Changes vs. Prior Period

• Significant Reduction in YTD Loss: The net loss for the six months ended June 30, 2024, decreased by approximately $21.3 million compared to the same period in 2023. This improvement is primarily due to the absence of a one-time $29.6 million expense for in-process research and development (IPR&D) related to the Flame Biosciences acquisition, which was expensed in Q1 2023.
• Increased R&D Spend (Quarterly): On a quarterly basis, R&D expenses increased by $6.8 million (from $11.1M to $17.9M) driven by expanded clinical trial activities for the DeFianCe and DisTinGuish studies, increased patient enrollment, and higher manufacturing costs.
• Capital Raise: In April 2024, the company completed a private placement raising approximately $40.0 million in gross proceeds ($37.1 million net), issuing 12.7 million shares of common stock and 1.5 million pre-funded warrants.
• Warrant Dividend: A non-cash dividend of $0.2 million was recorded due to the down-round feature of 2017 warrants triggered by the April 2024 financing.

Guidance, Outlook, and Risks

• Clinical Progress:
  • DKN-01 (DeFianCe Study): Updated data showed an Objective Response Rate (ORR) of 33% across all patients and 38% in patients with left-sided tumors. Enrollment in Part B is ongoing, with completion expected by September 2024; data expected mid-2025.
  • DKN-01 (DisTinGuish Study): Part C enrollment is ongoing in gastric/GEJ cancer patients. Initial data expected in Q4 2024 or early 2025.
• Liquidity Outlook: Management believes cash and cash equivalents of $78.5 million as of June 30, 2024, are sufficient to fund operations for at least the next 12 months. The company expects to continue generating operating losses.
• Risks:
  • Going Concern: The company has a history of losses and no approved products. Future operations depend on raising additional capital.
  • Clinical Uncertainty: There is no assurance that DKN-01 or FL-301 will receive regulatory approval or achieve commercial success.
  • Financing Needs: If additional funding is not obtained, the company may be forced to delay or eliminate clinical trials and reduce operating expenses.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the 12-month liquidity projection given the burn rate of ~$29 million over six months.
• Clinical Trial Enrollment: Confirm the status of enrollment for the DeFianCe Part B and DisTinGuish Part C studies against the stated timelines (Sept 2024 and Q4 2024/Early 2025).
• Dilution Impact: Review the impact of the April 2024 private placement and the repricing of 2017 warrants on future earnings per share and shareholder equity.
• R&D Incentive Reliance: Assess the dependency on Australian R&D tax incentives (approx. 43.5% of eligible expenses) and the risk of changes to this government program.
• Collaboration Agreements: Review the terms of the amended Adimab agreement and the status of the BeiGene collaboration (which is continuing as a clinical collaboration after BeiGene declined its option).